Erlotinib Unknown Status Phase 2 Trials for Lung, Carcinoma Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02066038Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation